RN7SL660P

Across TCGA pan-cancer cohorts, RN7SL660P RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RN7SL660P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RN7SL660P RNA is repressed in tumor relative to normal tissue. In most cancer types RN7SL660P is over-expressed in tumor, although a few such as KIRC and HNSC show the opposite, repressed pattern.

KIRC, HNSC, and HNSC are the cancer types where RN7SL660P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RN7SL660P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	−0.046	.008	3	view →
HNSC	Male	III,IV	+0.096	.036	2	view →
HNSC	Female	II,III,IV	−0.065	.036	2	view →
THCA	All	All	−0.061	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 3 lineages.

RN7SL660P–KIRC

Open the KIRC breakdown →